Zymosan-air-pouch inflammation, an ex perimental model of inflammation of an air pouch type induced on the back of rats with the aid of zymosan, was introduced in this laboratory as a novel experimental model of inflammation (1 ), which is characterized by an intense infiltration of polymorphonuclear leukocytes into the pouch fluid, marked aggregation of the leukocytes on the inner surface of the inflammatory pouch and formation of capsular granulomatous tissues as well as accumulation of exudate fluid in the pouch.
Activation of the alternative pathway of the complement system by zymosan has been assumed to be involved in the pathogenesis of the zymosan-air-pouch inflammation (1 ) .
The activation of the complement system brings about generation of chemotactic peptides (C5a and C5a des Arg) (2-4) and anaphylatoxins such as C3a, C4a and C5a (5-8), which are capable of inducing mast cell degranulation (5, 9, 10). The mast cell degranulation is immediately followed by release of vasoactive amines such as hista mine and serotonin from the granules liberated from the cells (9, 10) . Consequently, the degranulation is generally accompanied with elevation of vascular permeability in the local tissues (11) (12) (13) . Induction of zymosan-air-pouch inflam mation: The zymosan-air-pouch inflammation was induced as described (1) . In brief, rats were injected with 8.0 ml of air subcu taneously on the back under light ether anaesthesia to make an ellipsoid or oval air pouch. Twenty-four hours later, 4.0 ml of 1.6% (w/v) zymosan suspension in 0.8% (w/v) CMC solution in saline, supplemented with antibiotics (0.1 mg penicillin G potas sium and 0.1 mg dihydrostreptomycin sulfate per 1.0 ml), were injected into the preformed air-pouch to provoke an inflammatory response.
Materials and Methods

Animals
Induction of an inflammation of the air pouch type with compound 48/80: The air pouch was prepared on the back of rats as described above, and 24 hr later, 4.0 ml of 0.8% (w/v) CMC solution in saline con taining a potent mast cell degranulating agent, compound 48/80, at a concentration of 1 beg/ml and supplemented with the antibiotics previously described were injected into the preformed air-pouch to induce an inflam matory response. According to the literature, compound 48/80 at the above concentration is harmless to mast cells (14) . Measurement of CH50: At suitable times after the injection of the zymosan suspension or the vehicle into the air-pouch, rats were killed by cutting the carotid artery under light ether anaesthesia, and the fluid in the pouch was collected in a plastic cup. The pouch fluid collected was diluted twice with ice cold phosphate-buffered saline at pH 7.4 (PBS) and then centrifuged at 2,000 x g for 20 min at 4°C. The levels of complement in the pouch fluid supernatants were assayed according to the method of Mayer (1 5) with a modification (16) in which the volumes of samples and all the reagents were reduced to 1/5 of those in the original method, and the results were expressed in terms of CH50 in Mayer's unit.
Measurement of protein content: Protein content in the above supernatant of the pouch fluid was determined according to Lowry's method (17) using bovine serum albumin as a reference standard.
Measurement of histamine content: In order to remove protein from the above supernatant, 1.0 ml of it was mixed with 2.0 ml of 0.4 N HCIO4, and the mixture was centrifuged at 2,000 x g for 30 min at 4'C. Histamine content in the supernatant was assayed by the method of von Redlich and Glick (18) with a modification using each reagent and samples in 10 times the volume used in the original method.
Measurement of plasma exudation: Plasma exudation was measured with the aid of fluorescein-labeled bovine serum albumin (F BSA) as a tracer (19) which was prepared in our laboratory.
At a suitable time after injection into the preformed air-pouch of zymosan suspension, CMC solution con taining compound 48/80 or the vehicle, the rats were injected intravenously with 20 mg of F-BSA dissolved in 0.2 ml saline. Thirty minutes later the rats were killed and the entire pouch fluid was collected, diluted twice and centrifuged to collect the super natant and pellet separately. The supernatant was diluted four-fold with PBS and then fluorescence intensity was read at 521 nm under excitation at 490 nm. Total fluorescence intensity for the entire volume of the exudate was calculated and expressed in terms of percent of the amount of F-BSA injected and used as an index of the plasma exudation in the inflammatory locus.
Depletion of histamine and serotonin: Rats were depleted of their stores of histamine and serotonin by repeated injection of compound 48/80 according to the procedure described by Spector and Willoughby (20) Histological examination: Pouch wall tissues were excised together with the dorsal skin, fixed immediately in phosphate-buffered (pH 7.0) 3.7% (w/v) formaldehyde solution for 48 hr, embedded in paraffin, sectioned into 2 ,aim thick slices and stained with toluidine blue for histological examination.
Drug treatment: A histamine-H1 an tagonist, pyrilamine, and a serotonin an tagonist, methysergide, were dissolved in a small volume of distilled water and then mixed with the zymosan suspension or CMC solution containing compound 48/80. Those mixtures were injected into the preformed air-pouch to clarify the roles of histamine and serotonin.
Statistical analysis: Statistical analysis of the data was done by means of the F-test, and P values smaller than 0.05 were considered as significant. 
Results
Complement level and protein contents in the pouch fluid: A time course study on total protein contents and total CH50 titer for the entire pouch fluid collected from the inflam matory pouch was made and the results are shown in Fig. 1 . The total CH50 titer of the pouch fluid from rats with zymosan-air-pouch inflammation was significantly lower than that from control rats injected with the vehicle CMC solution in the air-pouch.
In contrast with the results for CH50, the total protein contents for the zymosan group were significantly higher than those for the control group.
Mast cell degranulation in the pouch wall tissues: Mast cells in subcutaneous tissues of the pouch wall in zymosan-air-pouch inflam mation were degranulated in part and many free metachromatic granules were observed around mast cells in the histological specimens (Fig. 2a) . In the control group, however, degranulation of mast cells in the pouch wall tissues was rarely observed in any of the specimens examined (Fig. 2b) .
Plasma exudation and histamine content in the pouch fluid: In the zymosan-air-pouch inflammation, the histamine level in the pouch fluid was abruptly raised immediately after injection with the zymosan suspension, and then it rapidly declined to approach the level of the control group injected with the vehicle CMC solution (Fig. 3b) . In close parallel with the change of histamine level in the zymosan group, the vascular per meability of the tissues surrounding the pouch greatly increased in the first 30 min period, and then in the subsequent 30 min period, the vascular permeability dropped to half of the preceding level (Fig. 3a) . In the control group injected with the vehicle CMC solution, the histamine level in the pouch fluid and plasma exudation were both maintained at very low levels throughout the experimental period of 6 hr. Histamine release and plasma exudation by compound 48/80 and zymosan: Compound 48/80, a potent histamine liberator, dissolved in 0.8% CMC solution was applied in the preformed air-pouch to induce mast cell degranulation and to enhance plasma exu dation. In this experiment, we attempted to investigate whether histamine liberated by compound 48/80 in an amount comparable to that in zymosan-air-pouch inflammation could induce increased plasma exudation to a level comparable to those observed in zymosan-air-pouch inflammation. Therefore, the dose-response relationship for the release of histamine and plasma exudation in the first 30 min periods after injection of various doses of compound 48/80 were investigated first. As summarized in Fig. 4 , compound 48/ 80 at concentrations less than 0.1 /cg/ml did not significantly increase plasma exudation, but 1 /cg/ml of compound 48/80, which does not injure mast cells at all (14) , provoked release of histamine to the same extent as found in zymosan-air-pouch inflammation. In contrast, the amount of plasma exudation induced by 1 ,,tg/ml of compound 48/80 was 50% less than that found in zymosan-air pouch inflammation. Thirty minutes later, rats were killed and histamine contents in the pouch fluid and plasma exudation into the pouch fluid were measured.
Each column represents the mean+S.E.M. from 5 animals. Statistically significant differences against the correspond ing control are shown by the following symbol: *P<0.001. Table 1 with those in Fig. 4 . In spite of marked reduction in histamine liberation to such a level as observed in the vehicle CMC group, zymosan was still stimulating the induction of plasma exudation in histamine-depleted rats to the extent thrice as high as those in the control group (Table 1) . In contrast with zymosan, ap plication of compound 48/80 to the pouch caused no significant increase in the vascular permeability. A couple of experiments were additionally performed using histamine depleted rats in an attempt to discover whether compound 48/80 reduces tissue reactivity to histamine.
These experiments were designed in order to examine whether the difference shown in Fig. 4 with respect to plasma exudation between the two groups treated with compound 48/80 (1 hg/ml) and zymosan might have been due to a possible direct inhibitory effect of compound 48/80 on the vascular permeability response to histamine. The results summarized in Table  1 
Discussion
We reported in the preceding paper that zymosan particles suspended in a solution of CIVIC, when injected into an air-pouch preformed on the back of rats, induced a typical inflammatory response characterized by accumulation of exudate fluid and poly morphonuclear leukocytes (PMNL) in the pouch (1). Moreover, zymosan caused the formation of an apparently aggregated layer of PMNL onto the inner surface of the pouch wall. Generation of proinflammatory frag ments, C3a and C5a, of complement via activation by zymosan of the alternative pathway of the complement system was assumed to play an important role in the mechanism of induction of this inflammatory response, since the anticomplementary agent K-76COONa was effective in inhibiting leukocyte accumulation in the inflammatory site (1 ) . The present experiments were undertaken to gain further insight into mechanisms of zymosan-induced inflam mation.
Protein contents in the pouch fluid from the zymosan-air pouch inflammation was always higher than those of the control pouch fluid (Fig. 1 a) , reflecting the higher level of the vascular permeability throughout the experimental period (Fig. 3a) . It is presumable, therefore, that the complement components exuded from the blood stream into the pouch fluid more actively in the zymosan group than in the vehicle CIVIC group. In marked contrast with the higher level of protein contents, however, the complement level as reflected by the CH5O titer in the pouch fluid from the zymosan-air-pouch inflammation was con siderably lower throughout the experimental period than that of the control (Fig. 1b) . It is likely, therefore, that the complement components exuded into the pouch fluid had been activated and consumed via the al ternative pathway in the presence of zymosan particles generating biologically active frag ments of the complement system such as C3a and C5a. The C3a and C5a anaphylatoxins thus generated are thought to stimulate mast cells to release their granular components containing histamine and serotonin. Liberation of histamine in the pouch fluid in the zymosan group has actually been confirmed, as shown in Fig. 3b . Degranulation of the mast cells in the zymosan group was also confirmed histologically (Fig. 2a) . All of these experimental results appear to indicate that histamine and serotonin liberated from mast cells were responsible for the abrupt rise in vascular permeability observed in the initial phase of zymosan-induced inflammation.
In addition to the demonstration of a definite role for mast cell degranulation in the initial increase in vascular permeability in zymosan-air-pouch inflammation, the data summarized in Fig. 4 appear to indicate that some mechanisms other than mast cell degranulation are also responsible in part for the vigorous plasma exudation in the zymosan group, since plasma exudation of the zymosan group was significantly higher than those of the compound 48/80 groups, whereas the histamine level of the zymosan group was rather lower than that of the compound 48/80 (1 /cg/ml) group. Elevation of vascular permeability induced by local application of compound 48/80 in the air pouch was almost completely counteracted by a combination treatment with a histamine antagonist, pyrilamine, and a serotonin antagonist, methysergide (Fig. 5) . In con trast, the combined treatment with pyrilamine and methysergide was much less effective in suppressing the vascular permeability response to zymosan (Fig. 5) . These facts also support the above-mentioned concept that some factors independent of mast cell degranulation play certain important roles in the initial rise of the vascular permeability in zymosan-induced inflammation.
